Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Harvard Business School
AstraZeneca
Dow
Moodys

Last Updated: January 28, 2023

Kyowa Kirin Company Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Kyowa Kirin
International Patents:98
US Patents:5
Tradenames:3
Ingredients:3
NDAs:3

Drugs and US Patents for Kyowa Kirin

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Kyowa Kirin NOURIANZ istradefylline TABLET;ORAL 022075-001 Aug 27, 2019 RX Yes No 7,541,363 See Plans and Pricing Y Y See Plans and Pricing
Kyowa Kirin NOURIANZ istradefylline TABLET;ORAL 022075-001 Aug 27, 2019 RX Yes No 7,727,993 See Plans and Pricing See Plans and Pricing
Kyowa Kirin NOURIANZ istradefylline TABLET;ORAL 022075-001 Aug 27, 2019 RX Yes No 8,318,201 See Plans and Pricing Y See Plans and Pricing
Kyowa Kirin FARESTON toremifene citrate TABLET;ORAL 020497-001 May 29, 1997 AB RX Yes Yes See Plans and Pricing See Plans and Pricing
Kyowa Kirin NOURIANZ istradefylline TABLET;ORAL 022075-002 Aug 27, 2019 RX Yes Yes 8,318,201 See Plans and Pricing Y See Plans and Pricing
Kyowa Kirin NOURIANZ istradefylline TABLET;ORAL 022075-002 Aug 27, 2019 RX Yes Yes 7,541,363 See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Kyowa Kirin

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Kyowa Kirin FARESTON toremifene citrate TABLET;ORAL 020497-001 May 29, 1997 4,696,949 See Plans and Pricing
Kyowa Kirin NOURIANZ istradefylline TABLET;ORAL 022075-002 Aug 27, 2019 7,727,994 See Plans and Pricing
Kyowa Kirin NOURIANZ istradefylline TABLET;ORAL 022075-001 Aug 27, 2019 7,727,994 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for KYOWA KIRIN drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Transdermal System 3.1 mg/24 hrs ➤ Subscribe 2015-10-09
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Dow
Harvard Business School
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.